A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis

Name: A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis
Creator: Vivli
Published: 2025-10-01 20:10:34
License: 暂无描述

DataCite Commons2025-10-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00011823/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)

提供机构：

Vivli

创建时间：

2025-10-01